Novo Nordisk A/S said Friday that its experimental drug ziltivekimab failed to reduce major adverse cardiovascular events in a Phase 3 trial [1, 2].
The results represent a significant setback for the company's efforts to target inflammation as a means of preventing heart disease complications. If successful, the drug would have provided a new therapeutic pathway for high-risk patients who remain vulnerable to cardiovascular events despite existing treatments.
The study, known as the ZEUS trial, tested whether ziltivekimab could lower the risk of heart-related complications by addressing systemic inflammation [1, 2]. The company said the drug did not demonstrate a benefit in reducing the risk of major adverse cardiovascular events when compared with a placebo [2].
Novo Nordisk had positioned the anti-inflammatory candidate as a potential addition to its cardiovascular portfolio. The failure of the ZEUS trial indicates that the specific inflammatory mechanism targeted by ziltivekimab may not be as effective in preventing clinical events as previously hypothesized [1].
The company did not provide further details on the specific data points from the trial in its initial announcement. However, the lack of a statistically significant reduction in events means the drug is unlikely to receive regulatory approval for this specific indication [2].
This outcome follows a broader industry trend of testing anti-inflammatory agents to complement cholesterol-lowering therapies. While some earlier studies suggested that inflammation plays a critical role in plaque stability, the results of the ziltivekimab trial suggest that blocking this particular pathway is not sufficient to alter patient outcomes in this high-risk group [1, 2].
“ziltivekimab failed to reduce the risk of major adverse cardiovascular events”
The failure of the ZEUS trial suggests that targeting inflammation alone may not be a viable standalone strategy for reducing major cardiovascular events in high-risk populations. For Novo Nordisk, this narrows the potential market for ziltivekimab and underscores the difficulty of translating biomarkers of inflammation into tangible clinical outcomes for heart disease patients.
